STERIS’ (TSE:STE – Free Report) – Research analysts at Raymond James reduced their FY2025 earnings per share estimates for shares of STERIS’ in a report released on Wednesday, April 9th. Raymond James analyst M. Barth now anticipates that the company will post earnings per share of $0.54 for the year, down from their prior forecast of $0.64. Raymond James currently has a “Hold” rating on the stock. Raymond James also issued estimates for STERIS’’s FY2027 earnings at $0.48 EPS.
Several other equities analysts have also recently weighed in on STE. Atb Cap Markets upgraded shares of STERIS’ to a “strong-buy” rating in a research note on Sunday, December 22nd. Cormark upgraded shares of STERIS’ to a “moderate buy” rating in a research note on Monday, January 6th.
STERIS’ Stock Performance
STERIS’ Company Profile
STERIS’s MISSION IS TO HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science product and service solutions around the globe by providing innovative healthcare and life science product and service solutions around the globe.
Further Reading
- Five stocks we like better than STERIS’
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Robinhood Strategies Could Be a Game-Changer for Young Investors
- A Deeper Look at Bid-Ask Spreads
- Are These 3 Retail Stocks Oversold or Really in Trouble?
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead
Receive News & Ratings for STERIS’ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS’ and related companies with MarketBeat.com's FREE daily email newsletter.
